WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018034620) IMMUNOSUPPRESSIVE COMPOSITION FOR USE IN TREATING IMMUNOLOGICAL DISORDERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/034620 International Application No.: PCT/SG2017/050408
Publication Date: 22.02.2018 International Filing Date: 18.08.2017
IPC:
A61K 39/395 (2006.01) ,C07K 16/24 (2006.01) ,A61K 38/19 (2006.01) ,A61K 38/20 (2006.01) ,A61P 3/00 (2006.01) ,A61P 3/06 (2006.01)
Applicants: SINGAPORE HEALTH SERVICES PTE LTD[SG/SG]; 31 Third Hospital Avenue, #03-03, Bowyer Block C, Singapore 168753, SG
Inventors: FAN, Xiubo; SG
HWANG, William Ying Khee; SG
Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531 Robinson Road Post Office, Singapore 903031, SG
Priority Data:
10201606949Q19.08.2016SG
Title (EN) IMMUNOSUPPRESSIVE COMPOSITION FOR USE IN TREATING IMMUNOLOGICAL DISORDERS
(FR) COMPOSITION IMMUNOSUPPRESSANTE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE TROUBLES IMMUNOLOGIQUES
Abstract: front page image
(EN) The present disclosure describes a pharmaceutical composition comprising at least one antibody targeting one or more of cytokines selected from Macrophage colony-stimulating factor (M-CSF), lnterleukin-1 beta (IL-1 β), CCL-1 (I- 309) and Eotaxin-2 (CCL24) and at least one mesenchymal stromal cell-derived protein selected from Prostaglandin E2 (PGE2), Osteoprotegerin (OPG), CCL7 (MCP-3), CCL8 (MCP-2), CCL20 (MIP-3α), CXCL5 (ENA-78), Interleukin 10 (IL-10) and CXCL6 (GCP-2). In a preferred embodiment, a composition comprising anti-CCL24 antibody and CXCL5 is disclosed. The present disclosure also describes the use of said pharmaceutical composition for treating immunological diseases, for example alloimmune or autoimmune diseases and further discloses the use of the pharmaceutical composition for immunomodulation.
(FR) La présente invention concerne une composition pharmaceutique comprenant au moins un anticorps ciblant une ou plusieurs cytokines choisies parmi le facteur de stimulation des colonies de macrophages (M-CSF), l'interleukine-1 bêta (IL-1 β), la CCL-1 (I-309) et l'éotaxine-2 (CCL24) et au moins une protéine dérivée d'une cellule stromale mésenchymateuse choisie parmi la prostaglandine E2 (PGE2), l'ostéoprotégérine (OPG), la CCL7 (MCP-3), la CCL8 (MCP-2), la CCL20 (MIP-3α), la CXCL5 (ENA-78), l’interleukine 10 (IL-10) et la CXCL6 (GCP-2). Dans un mode de réalisation préféré, la présente invention concerne une composition comprenant un anticorps anti-CCL24 et une CXCL5. La présente invention concerne également l'utilisation de ladite composition pharmaceutique dans le traitement de maladies immunologiques, par exemple des maladies allo-immunes ou auto-immunes, ainsi que l'utilisation de la composition pharmaceutique pour immunomodulation.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)